Puma Biotechnology (PBYI) Shares Down 5.2%
Puma Biotechnology Inc (NASDAQ:PBYI) shares dropped 5.2% during trading on Friday . The company traded as low as $99.45 and last traded at $99.70. Approximately 567,900 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 1,082,815 shares. The stock had previously closed at $105.20.
PBYI has been the subject of a number of recent research reports. Credit Suisse Group lifted their price objective on Puma Biotechnology from $118.00 to $136.00 and gave the company an “outperform” rating in a research note on Monday, September 11th. Leerink Swann lifted their price objective on Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Stifel Nicolaus lifted their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, October 2nd. Finally, Bank of America reiterated a “buy” rating and set a $135.00 price objective (up previously from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $130.67.
Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $3.78 million. During the same quarter in the previous year, the firm posted ($1.11) EPS. equities research analysts anticipate that Puma Biotechnology Inc will post -8.19 EPS for the current year.
Several institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Puma Biotechnology in the 3rd quarter worth $2,279,000. California Public Employees Retirement System grew its holdings in shares of Puma Biotechnology by 0.7% in the third quarter. California Public Employees Retirement System now owns 108,000 shares of the biopharmaceutical company’s stock worth $12,933,000 after acquiring an additional 800 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of Puma Biotechnology by 265.6% in the third quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock worth $57,743,000 after acquiring an additional 350,300 shares during the period. Perceptive Advisors LLC grew its holdings in shares of Puma Biotechnology by 26.0% in the third quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock worth $110,627,000 after acquiring an additional 190,500 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in shares of Puma Biotechnology by 1.8% in the third quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock worth $226,435,000 after acquiring an additional 33,270 shares during the period. 96.05% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology (PBYI) Shares Down 5.2%” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/puma-biotechnology-pbyi-shares-down-5-2/1766388.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.